Research Analysts Set Expectations for Cara Therapeutics Inc’s FY2018 Earnings (CARA)

Cara Therapeutics Inc (NASDAQ:CARA) – Equities research analysts at Piper Jaffray Companies decreased their FY2018 earnings per share estimates for Cara Therapeutics in a research report issued to clients and investors on Tuesday, November 6th. Piper Jaffray Companies analyst D. Amsellem now expects that the biopharmaceutical company will post earnings of ($2.02) per share for the year, down from their prior estimate of ($1.83). Piper Jaffray Companies also issued estimates for Cara Therapeutics’ Q4 2018 earnings at ($0.49) EPS, Q1 2019 earnings at ($0.53) EPS, Q2 2019 earnings at ($0.51) EPS, Q3 2019 earnings at ($0.44) EPS, Q4 2019 earnings at ($0.41) EPS, FY2019 earnings at ($1.90) EPS, FY2020 earnings at ($1.90) EPS and FY2021 earnings at ($1.90) EPS.

Other equities research analysts have also issued reports about the company. BidaskClub lowered Cara Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, July 31st. Stifel Nicolaus lifted their price objective on Cara Therapeutics from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, August 8th. HC Wainwright set a $26.00 price objective on Cara Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 8th. Zacks Investment Research upgraded Cara Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, July 30th. Finally, Canaccord Genuity raised their target price on Cara Therapeutics from $22.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, August 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $26.11.

Shares of CARA stock opened at $19.67 on Friday. The company has a market capitalization of $774.41 million, a PE ratio of -10.58 and a beta of 2.92. Cara Therapeutics has a fifty-two week low of $11.46 and a fifty-two week high of $24.30.

Cara Therapeutics (NASDAQ:CARA) last issued its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.05). The firm had revenue of $5.06 million during the quarter, compared to analysts’ expectations of $4.72 million.

In other Cara Therapeutics news, CEO Derek T. Chalmers sold 20,000 shares of Cara Therapeutics stock in a transaction on Thursday, November 1st. The stock was sold at an average price of $18.78, for a total transaction of $375,600.00. Following the completion of the transaction, the chief executive officer now owns 991,392 shares in the company, valued at $18,618,341.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Frederique Ph.D. Menzaghi sold 3,000 shares of Cara Therapeutics stock in a transaction on Monday, October 1st. The shares were sold at an average price of $23.99, for a total value of $71,970.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 99,484 shares of company stock valued at $2,044,195. 6.70% of the stock is currently owned by company insiders.

A number of large investors have recently made changes to their positions in CARA. Exane Derivatives purchased a new position in Cara Therapeutics during the second quarter valued at $138,000. Creative Planning purchased a new position in Cara Therapeutics during the third quarter valued at $207,000. BB&T Securities LLC purchased a new position in Cara Therapeutics during the second quarter valued at $218,000. Rathbone Brothers plc purchased a new position in Cara Therapeutics during the third quarter valued at $228,000. Finally, Raymond James & Associates purchased a new position in Cara Therapeutics during the second quarter valued at $250,000. Institutional investors and hedge funds own 48.88% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

Read More: Fundamental Analysis and Choosing Stocks

Earnings History and Estimates for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply